生长激素给药改善超重/肥胖人群的非酒精性脂肪性肝病:一项随机试验
这项为期6个月的随机双盲安慰剂对照试验纳入53例BMI≥25 kg/m²且无糖尿病的非酒精性脂肪性肝病成人,随机接受每日皮下生长激素或安慰剂,目标将胰岛素样生长因子1调至正常上限四分位。结果显示生长激素组肝内脂质绝对百分比降幅显著大于安慰剂组,血糖指标未恶化。
要点
- 生长激素组肝内脂质绝对百分比平均下降5.2%,安慰剂组平均上升3.8%,组间差异显著(P=0.009)。
- 净平均治疗效应为-8.9%(95%CI,-14.5至-3.3%)。
- 除无临床意义的下肢水肿外,两组副作用相似,血糖指标变化无显著差异。
核心结论
- 生长激素给药可减少超重/肥胖且非酒精性脂肪性肝病成人的肝脏脂肪变性,且不加重血糖指标。
- 生长激素/胰岛素样生长因子1轴可能成为非酒精性脂肪性肝病未来的治疗靶点。
研究设计与样本
- 为期6个月的随机双盲安慰剂对照试验,纳入53例年龄18至65岁、BMI≥25 kg/m²且无糖尿病的非酒精性脂肪性肝病成人。
- 受试者随机接受每日皮下生长激素或安慰剂,目标将胰岛素样生长因子1调至正常上限四分位。
- 主要终点为治疗前及6个月时通过质子磁共振波谱(1H-MRS)评估的肝内脂质含量。
主要发现
- 随机分组为生长激素组27例、安慰剂组26例,6个月时完成者41例(生长激素组20例、安慰剂组21例)。
- 1H-MRS测得的肝内脂质绝对百分比降幅在生长激素组显著大于安慰剂组(均值±标准差:-5.2±10.5% vs 3.8±6.9%;P=0.009)。
- 净平均治疗效应为-8.9%(95%CI,-14.5至-3.3%)。
- 除无临床意义的下肢水肿在生长激素组较安慰剂组更频繁外(21% vs 0%,P=0.02),所有副作用在两组间相似。
- 无因血糖状态恶化而退出研究者,且生长激素组与安慰剂组在血糖指标或胰岛素抵抗变化方面无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Overweight and obesity are associated with relative growth hormone (GH) deficiency, which has been implicated in the development of nonalcoholic fatty liver disease (NAFLD). NAFLD is a progressive disease without effective treatments. OBJECTIVE: We hypothesized that GH administration would reduce hepatic steatosis in individuals with overweight/obesity and NAFLD. METHODS: In this 6-month randomized, double-blind, placebo-controlled trial of low-dose GH administration, 53 adults aged 18 to 65 years with BMI ≥25 kg/m2 and NAFLD without diabetes were randomized to daily subcutaneous GH or placebo, targeting insulin-like growth factor 1 (IGF-1) to the upper normal quartile. The primary endpoint was intrahepatic lipid content (IHL) by proton magnetic resonance spectroscopy (1H-MRS) assessed before treatment and at 6 months. RESULTS: Subjects were randomly assigned to a treatment group (27 GH; 26 placebo), with 41 completers (20 GH and 21 placebo) at 6 months. Reduction in absolute % IHL by 1H-MRS was significantly greater in the GH vs placebo group (mean ± SD: -5.2 ± 10.5% vs 3.8 ± 6.9%; P = .009), resulting in a net mean treatment effect of -8.9% (95% CI, -14.5 to -3.3%). All side effects were similar between groups, except for non-clinically significant lower extremity edema, which was more frequent in the GH vs placebo group (21% vs 0%, P = .02). There were no study discontinuations due to worsening of glycemic status, and there were no significant differences in change in glycemic measures or insulin resistance between the GH and placebo groups. CONCLUSION: GH administration reduces hepatic steatosis in adults with overweight/obesity and NAFLD without worsening glycemic measures. The GH/IGF-1 axis may lead to future therapeutic targets for NAFLD.
引用
- Dichtel LE, Corey KE, Haines MS, et al. Growth Hormone Administration Improves Nonalcoholic Fatty Liver Disease in Overweight/Obesity: A Randomized Trial. J Clin Endocrinol Metab. 2023. PMID: 37379033. doi:10.1210/clinem/dgad375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。